EUCTR2015-000190-12-PL进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Present with chronic plaque Ps based on a diagnosis of chronic Ps vulgaris for at least 6 months prior to baseline as determined by the investigator.
- •[2]Have =10% body surface area (BSA) involvement at screening and baseline.
- •[3]Have both an sPGA score of =3 and PASI score of =12 at screening and baseline.
- •[4]Are a candidate for phototherapy and/or systemic therapy.
- •[5]Are male or female patients 18 years or older.
- •[6]If a male patient, patient agrees to use a reliable method of birth control during the study.
- •[7]If a female patient:
- •Are women of childbearing potential who are determined to be negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of investigational product, whichever is longer. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel.
- •Are women of non-childbearing potential, defined as:
- •Women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation);
- •Women who are =60 years of age
- •Women =40 and <60 years of age who have had a cessation of menses for =12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (=40 mIU/mL).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1107
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 93
排除标准
- •[9]Have predominant pattern of pustular, erythrodermic, and/or guttate forms of Ps
- •[10]Have a history of drug-induced Ps
- •[11]Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study, per investigator assessment
- •[12]Have had any of the following therapies within 4 weeks prior to baseline: systemic non-biologic Ps therapy (including, but not limited to, psoralens and ultraviolet A [PUVA] light therapy; cyclosporine; corticosteroids; Methotrexate; apremilast; tofacitinib; oral retinoids; mycophenolate mofetil; thioguanine; hydroxyurea; sirolimus; azathioprine; fumaric acid derivatives; or 1, 25 dihydroxy vitamin D3 and analogs) or phototherapy (including UVB or self-treatment with tanning beds or therapeutic sunbathing) or topical Ps therapy with psoralens.
- •Have had any of the following therapies within 2 weeks prior to baseline: topical Ps treatment (including, but not limited to, corticosteroids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, emollients, and other non-prescription topical products containing salicylic acid, or alpha- or beta-hydroxyl acids, and medicated shampoos [for example, those that contain corticosteroids, coal tar, or vitamin D3 analogs])
- •Exceptions: topical steroids will be permitted for use limited to the face, axilla, and/or genitalia
- •[13]Concurrent or recent use of any biologic agent within the following washout periods prior to baseline: etanercept <28 days; infliximab or adalimumab <60 days; golimumab <90 days; ustekinumab <8 months; rituximab <12 months; secukinumab <5 months; or any other biologic agent <5 half-lives
- •[14]Have ever received natalizumab or other agents that target alpha-4-integrin
- •[15]Have previously failed to respond to an IL-17 antagonist, per investigator assessment
- •[16]Have previously completed or withdrawn from this study, or participated in any other study with ixekizumab
- •[17]Had a live vaccination within 12 weeks prior to baseline, or intend to have a live vaccination during the course of the study or within 12 weeks of completing treatment in this study, or have participated in a vaccine clinical study within 12 weeks prior to baseline. Investigators should review the vaccination status of their patients and follow the local guidelines for adult vaccination with non-live vaccines intended to prevent infectious disease prior to therapy
- •[18]Had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months prior to baseline (Week 0), or intend to have this vaccination with BCG during the course of the study or within 12 months of completing treatment in this study
- •[19]Have a known allergy or hypersensitivity to any biologic therapy that would pose an unacceptable risk to the patient if participating in this study.
- •[20]Are currently enrolled in, have participated, or discontinued from a clinical trial involving an investigational product or nonapproved use of a drug or device within the last 30 days or a period of at least 5 half-lives of the last administration of the drug, whichever is longer, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer - VENICEPatients with metastatic androgen-independent prostate cancerEUCTR2006-004756-20-DKsanofi-aventis recherche & développement1,200
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer - VENICEPatients with metastatic androgen-independent prostate cancerEUCTR2006-004756-20-GBsanofi-aventis recherche & développement1,200
进行中（未招募）
1 期
A clinical trial in patients with moderate to severe plaque psoriasis comparing the efficacy and safety of taking a drug called Ixekizumab either every 4 weeks or every 2 weeks.EUCTR2015-000190-12-CZEli Lilly and Company1,200
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer - VENICEEUCTR2006-004756-20-FRsanofi-aventis recherche & développement1,200
进行中（未招募）
1 期
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)EUCTR2015-002628-14-NL146